Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial.

Abstract

HomeJournal of the American Heart AssociationVol. 7, No. 12Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial Open AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citations ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessCorrectionPDF/EPUBInteraction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial Originally published17 Jun 2018https://doi.org/10.1161/JAHA.117.004259Journal of the American Heart Association. 2018;7:e004259This article corrects the followingInteraction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT TrialCorrectionIn the article by Varma et al, “Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial,” which published online May 27, 2018, and appeared in the June 5, 2018 issue of the journal (J Am Heart Assoc. 2018;7:e009592 DOI: 10.1161/JAHA.118.009592), on page 12, in the Disclosures section, the acknowledgement of individual research grants and consulting fees unrelated to the study had not been stated. These have now been added.Individual disclosures are: Varma: consulting fees from Biotronik, Abbott, Medtronic; Sogaard: Research grants from BIOTRONIK and GE Health Care; Consultant AstraZenaca and BIOTRONIK; Bax: department received unrestricted research grants from Biotronik, Medtronic, Boston Scientific, Ge Healthcare, and Edwards Lifescience; Abraham: consulting fees from Biotronik; Borer: consulting fees from Amgen, Servier, Pfizer, AstraZeneca, GTilead, General Electric, GSK, Novartis, and ARMGO; Dickstein: none; Singh: consulting fees from Abbott, Boston Sci, Biotronik, MEDTRONIC, Liva Nova, Impulse dynamics; Gras: consulting fees from Medtronic, Biotronik, Abbott (Saint jude medical), Boston; Holzmeister: consulting fees from Biotronik; Brugada: consulting fees from Biotronik; Ruschitzka: research grants from St Jude Medical, Novartis; personal fees for lectures from St Jude Medical, Servier, Zoll, Novartis, Bayer, and Abbott; personal fees for advisory board or steering committee clinical trial meetings from AstraZeneca, Sanofi, Cardiorentis, Amgen, BMS, Pfizer, Fresenius, Vifor, and Rochen.The authors regret the error.The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/7/11/e009592.Footnotes Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesInteraction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT TrialFrank Ruschitzka, et al. Journal of the American Heart Association. 2018;7 June 19, 2018Vol 7, Issue 12Article InformationMetrics Copyright © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley BlackwellThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.https://doi.org/10.1161/JAHA.117.004259PMID: 29910191 Originally publishedJune 17, 2018 PDF download